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Introduction
Acute kidney injury (AKI) is common and imposes a 
heavy burden of illness (morbidity and mortality). 
Further more, the costs of care for patients with AKI are 
high and there is considerable variability in practice. AKI 
is amenable to prevention, early detection and treatment. 
Clinical practice guidelines in the ﬁ eld thus have the 
potential to reduce variations, improve outcomes, and 
reduce costs.
Care of the critically ill patient with AKI requires co-
ordination of care across multiple disciplines in a variety 
of settings. Th is year, Kidney Disease: Improving Global 
Outcomes (KDIGO), a nonproﬁ t foundation, has 
published the ﬁ rst international, interdisciplinary clinical 
practice guideline on AKI [1], which is also available in its 
entirety on the KDIGO website [2]. We present here a 
shortened version of the guideline focusing on deﬁ ni-
tions, risk assessment, evaluation, and nondialytic 
manage ment; we also provide additional rationale and 
commentary for those recommendation statements that 
most directly impact the practice of critical care.
Methods
A complete and detailed description of the methods can 
been found online [3]. Th e KDIGO Co-Chairs appointed 
two Co-Chairs of the Work Group, who then assembled 
experts in several domains (nephrology, critical care 
medicine, internal medicine, pediatrics, cardiology, 
radiology, infectious diseases, and epidemiology). Th e 
Evidence Review Team at Tufts Medical Center, Boston, 
MA, USA consisted of physician-methodologists with 
exper tise in nephrology and internal medicine, and 
research associates and assistants.
Th e evidence selection, appraisal, and presentation 
have followed methodology previously described in 
KDIGO clinical practice guidelines [4]. Work Group 
members reviewed all retrieved relevant articles, data 
extraction forms, summary tables, and evidence proﬁ les 
for accuracy and completeness. Th e four major topic 
areas of interest for AKI included: deﬁ nition and classi-
ﬁ cation; prevention; pharmacologic treatment; and renal 
replacement therapy (RRT). Populations of interest were 
those at risk for AKI (including those after intravascular 
contrast-media exposure, aminoglycosides, and ampho-
tericin), and those with AKI or at risk for AKI with a 
focus on patients with sepsis or trauma, receiving critical 
care, or undergoing cardiothoracic surgery. We excluded 
studies on AKI from rhabdomyolysis, speciﬁ c infections, 
and poisoning or drug overdose. Overall, we screened 
18,385 citations.
Outcome selection, judgments, values, and preferences
We limited outcomes to those important for decision-
making, including development of AKI, need for or 
dependence on RRT, and all-cause mortality. When 
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weight ing the evidence across diﬀ erent outcomes, we 
selected as the crucial outcome that which weighed most 
heavily in the assessment of the overall quality of 
evidence. Values and preferences articulated by the Work 
Group included: a desire to be inclusive in terms of 
meeting criteria for AKI; a progressive approach to risk 
and cost such that, as severity increased, the group put 
greater value on possible eﬀ ectiveness of strategies, but 
maintained high value for avoidance of harm; and intent 
to guide practice but not limit future research.
Grading the quality of evidence and the strength of 
recommendations
Th e grading approach followed in this guideline and the 
wording of each recommendation are adopted from the 
Grading of Recommendations Assessment, Development 
and Evaluation system [4,5]. Th e strength of each recom-
mendation is rated as level 1 (strong) or level 2 (weak or 
discretionary). In addition, each statement is assigned a 
grade for the quality of the supporting evidence: A (high), 
B (moderate), C (low), or D (very low). Furthermore, on 
topics that cannot be subjected to systematic evidence 
review, the Work Group issued statements that are not 
graded which hopefully will provide general guidance 
that is based on clinical experience.
Th e Grading of Recommendations Assessment, 
Develop ment and Evaluation system is best suited to 
evaluate evidence on comparative eﬀ ectiveness. Some of 
our most important guideline topics involve diagnosis 
and staging of AKI, and here the Work Group chose to 
provide un graded statements. Th ese statements are 
indirectly sup ported by evidence on risk relationships 
and resulted from unanimous consensus of the Work 
Group and should not be viewed as weaker than graded 
recommendations.
Recommendations and rationale
Th e Work Group developed 61 graded recommendation 
statements and 26 ungraded statements. Th e six major 
domains are: (A) deﬁ nition and staging; (B) risk assess-
ment; (C) evaluation and general management; (D) 
preven tion and treatment; (E) contrast-induced AKI; and 
(F) RRT for AKI. Domains (A) through (D) are presented 
here while domains (E) and (F) are presented in Lameire 
et al. immediately following this review.
A. Defi nition and staging of AKI
AKI is deﬁ ned by an abrupt decrease in kidney function 
that includes, but is not limited to, acute renal failure. 
AKI is a broad clinical syndrome encompassing various 
etiologies, including pre-renal azotemia, acute tubular 
necrosis, acute interstitial nephritis, acute glomerular 
and vasculitic renal diseases, and acute postrenal ob-
struc tive nephropathy. More than one of these conditions 
may coexist in the same patient and epidemiological 
evidence supports the notion that even mild, reversible 
AKI has important clinical consequences, including 
increased risk of death [6,7]. AKI can thus be considered 
more like acute lung injury or acute coronary syndrome. 
Furthermore, because the manifestations and clinical 
consequences of AKI can be quite similar (even 
indistinguishable) regard less of whether the etiology is 
predominantly within the kidney or predominantly from 
outside stresses on the kidney, the syndrome of AKI 
encompasses both direct injury to the kidney as well as 
acute impairment of function.
Th e Acute Dialysis Quality Initiative group developed 
the Risk, Injury, Failure; Loss and End-stage kidney 
disease (RIFLE) system for diagnosis and classiﬁ cation of 
a broad range of acute impairment of kidney function 
through a broad consensus of experts [8]. Studies totaling 
over 0.5  million patients from around the world have 
shown that AKI deﬁ ned by RIFLE is associated with 
decreased survival and that increasing RIFLE stage leads 
to increased risk of death [9-14].
More recently, the Acute Kidney Injury Network en-
dorsed the RIFLE criteria with a modiﬁ cation to include 
small changes in serum creatinine (SCr) (≥0.3  mg/dl or 
26.5  μmol/l) when they occur within a 48-hour period 
[15]. Two recent studies examining large databases in the 
USA [12] and Europe [13] validated these modiﬁ ed 
criteria. Th akar and colleagues found that increased 
severity of AKI was associated with an increased risk of 
death independent of comorbidity [12]. Patients with 
stage 1 AKI (≥0.3  mg/dl or 26.5  μmol/l increase in SCr 
but less than a twofold increase) had an odds ratio of 2.2; 
in patients with stage 2 AKI (corresponding to RIFLE-I) 
there was an odds ratio of 6.1; and in stage 3 AKI patients 
(RIFLE-F) the odds ratio was 8.6 for hospital mortality. 
An additional modiﬁ cation to the RIFLE criteria has been 
proposed for pediatric patients in order to better classify 
small children with acute-on-chronic disease [16].
Unfortunately, the existing criteria  – while useful and 
widely validated – are still limited. First, despite eﬀ orts to 
standardize the deﬁ nition and classiﬁ cation of AKI, there 
is still inconsistency in application [10,11]. A minority of 
studies have included urinary output criteria despite their 
apparent ability to identify additional cases [13,17] and 
many studies have excluded patients whose initial SCr is 
already elevated. Preliminary data suggest that roughly 
one-third of AKI cases are community acquired [18] and 
many cases may be missed by limiting analysis to 
documented increases in SCr. Indeed, the majority of 
cases of AKI in the developing world are likely to be 
community acquired. Few studies can thus provide 
accurate incidence data. An additional problem relates to 
the limitations of SCr and urine output for detecting AKI. 
In the future, biomarkers of renal cell injury may identify 
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additional patients with AKI and may identify the 
majority of patients at an earlier stage. Th ese concerns 
notwithstanding, and in view of the available evidence, 
the Work Group accepted the existing criteria for the 
diagnosis and staging of AKI and proposed a single 
deﬁ nition of AKI that should be useful for practice, 
research, and public health.
A1:  AKI is deﬁ ned as any of the following (not 
graded):
• increase in SCr by ≥0.3 mg/dl (≥26.5 μmol/l) 
within 48 hours; or
• increase in SCr to ≥1.5 times baseline, which 
is known or presumed to have occurred 
within the prior 7 days; or
• urine volume <0.5 ml/kg/hour for 6 hours.
A2:  AKI is staged for severity according to the 
criteria presented in Table 1 (not graded).
A3:  Th e cause of AKI should be determined 
whenever possible (not graded).
B. Risk assessment
Th ere are many types of exposure that may cause AKI. 
However, the chances of developing AKI after exposure 
to the same insult depend on a number of susceptibility 
factors that vary widely from individual to individual. 
Our understanding of susceptibility factors is based on 
many observational studies that address diﬀ erent settings 
with regards to the type, severity, duration, and multi-
plicity of insults. While this heterogeneity provides 
insight into some susceptibility factors that are common 
across various populations, the generalizability of results 
from one particular setting to the next is uncertain.
It is important to screen patients who have undergone 
an exposure (Table 2) and to continue monitoring high-
risk patients until the risk has subsided. Exact intervals 
for checking SCr and for which individuals’ urine output 
should be monitored remain matters of clinical judgment; 
however, as a general rule, high-risk in-patients should 
have SCr measured at least daily and more frequently 
after an exposure, and critically ill patients should 
undergo urine output monitoring. Th is will necessitate 
urinary bladder catheterization in many cases, and the 
risks of infection should also be considered in the 
monitoring plan. Many opportunities for prevention and 
earlier recognition of AKI at emergency admissions may 
be missed. For example, a recent clinical practice 
assessment of emer gency admissions in the UK highlights 
missed oppor tu nities for prevention and earlier 
recognition of AKI [19].
B1:  We recommend that patients be stratiﬁ ed for 
risk of AKI according to their susceptibilities 
and exposures (Grade 1B).
B2: Manage patients according to their 
susceptibilities and exposures to reduce the risk 
of AKI (see relevant guideline sections) (not 
graded).
B3:  Test patients at increased risk for AKI with 
measurements of SCr and urine output to 
detect AKI (not graded). Individualize 
frequency and duration of monitoring based on 
patient risk and clinical course (not graded).
C. Evaluation and general management
AKI is one of a number of conditions that aﬀ ect kidney 
structure and function. Because the manifestations and 
clinical consequences of AKI can be quite similar (even 
indistinguishable) regardless of whether the etiology is 
predominantly within the kidney or predominantly from 
outside stresses on the kidney, the syndrome of AKI 
encompasses both direct injury to the kidney as well as 
acute impairment of function. Since treatments of AKI 
are dependent to a large degree on the underlying 
etiology, this guideline focuses on speciﬁ c diagnostic 
Table 1. Staging of acute kidney injury
Stage Serum creatinine Urine output
1 1.5 to 1.9 times baseline or ≥0.3 mg/dl (≥26.5 μmol/l) increase <0.5 ml/kg/hour for 6 to 12 hours
2 2.0 to 2.9 times baseline <0.5 ml/kg/hour for ≥12 hours
3 3.0 times baseline or increase in serum creatinine to ≥4.0 mg/dl (≥353.6 μmol/l) or  <0.3 ml/kg/hour for ≥24 hours or anuria for ≥12 hours
 initiation of renal replacement therapy or in patients <18 years a decrease in eGFR to 
 <35 ml/minute per 1.73 m2
eGFR, estimated glomerular fi ltration rate.
Table 2. Causes of acute kidney injury: exposures and 
susceptibilities for nonspecifi c acute kidney injury
Exposure Susceptibility
Sepsis Dehydration or volume depletion 
Critical illness Advanced age
Circulatory shock Female gender
Burns Black race
Trauma Chronic kidney disease
Cardiac surgery (especially with  Chronic diseases (heart, lung, liver)
cardiopulmonary bypass)
Major noncardiac surgery Diabetes mellitus
Nephrotoxic drugs Cancer
Radiocontrast agents Anemia
Poisonous plants and animals 
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approaches (Figure 1). However, since general therapeutic 
and monitoring recommendations can be made regarding 
all forms of AKI, our approach will be to begin with 
general measures (Figure 2).
Th e clinical evaluation of AKI includes a careful history 
and thorough physical examination. Drug history should 
include over-the-counter formulations and herbal 
remedies or recreational drugs. Th e social history should 
include exposure to tropical diseases, and physical 
examination should include evaluation of ﬂ uid status, 
signs for acute and chronic heart failure, and infection. 
Measurement of cardiac function and intra-abdominal 
pressure should be considered in the appropriate clinical 
context. Laboratory parameters  – including SCr, blood 
urea nitrogen, and electrolytes, complete blood count 
and diﬀ erential – should be obtained. Urine analysis and 
microscopic examination as well as urinary chemistries 
may be helpful in determining the underlying cause of 
AKI. Imaging tests, especially ultrasound, are important 
components of the evaluation for patients with AKI. 
Finally, a number of biomarkers of functional change and 
cellular damage are under evaluation for early diagnosis 
of AKI, risk assessment for AKI, and prognosis of AKI. 
Although an evidence-based analysis of the role of 
biomarkers was beyond the scope of this guideline, recent 
work suggests in particular that the prognostic utility of 
newer urinary biomarkers – including neutrophil 
gelatinase-associated lipocalin, kidney injury molecule-1, 
and IL-18  – added to urine microscopic examination is 
signiﬁ cantly higher over clinical assessment alone [20].
Because the stage of AKI has clearly been shown to 
correlate with short-term [6,7,11,13] and even longer-
term outcomes [21], it is advisable to tailor management 
to AKI stage. Figure 2 lists a set of actions that should be 
considered for patients with AKI. Note that for patients 
at increased risk, these actions begin even before AKI is 
diagnosed. Note also that management and diagnostic 
steps are both included in this ﬁ gure. Th is is because 
response to therapy is an important part of the diagnostic 
approach. Th ere are few speciﬁ c tests to establish the 
etiology of AKI. However, a patient’s response to treat-
ment (for example, discontinuation of a possible 
nephrotoxic agent) provides important information as to 
the diagnosis.
C1: Evaluate patients with AKI promptly to 
determine the cause, with special attention to 
reversible causes (not graded).
C2: Monitor patients with AKI with measurements 
of SCr and urine output to stage the severity, 
according to Recommendation A2 (not graded).
C3: Manage patients with AKI according to the 
stage (see Figure 2) and cause (not graded).
C4: Evaluate patients 3 months after AKI for 
resolution, new onset, or worsening of 
pre-existing chronic kidney disease (CKD) (not 
graded).
• If patients have CKD, manage these patients 
as detailed in the Kidney Disease Outcomes 
Quality Initiative chronic kidney disease 
(CKD) guideline (Guidelines 7 to 15) (not 
graded).
• If patients do not have CKD, consider them 
to be at increased risk for CKD and care for 
them as detailed in the Kidney Disease 
Outcomes Quality Initiative CKD 
Figure 1. Evaluation of acute kidney injury. AKI, acute kidney 
injury; GN, glomerulonephritis.
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Guideline 3 for patients at increased risk for 
CKD (not graded).
D. Prevention and treatment of AKI
Fluids and vasopressors
Despite the recognition of volume depletion as an impor-
tant risk factor for AKI, there have been no randomized 
controlled trials (RCTs) that directly evaluated the role of 
ﬂ uids versus placebo in the prevention of AKI, except in 
the ﬁ eld of contrast-induced AKI (see Lameire et al. 
immediately following this review). While ﬂ uid resusci-
tation is widely believed to be protective, large multi-
center studies have also shown that a positive ﬂ uid 
balance is associated with increased 60-day mortality 
[22-24].
Results of the Saline vs. Albumin Fluid Evaluation 
study  – a RCT comparing 4% human albumin in 0.9% 
saline with isotonic saline in ICU patients  – indicated 
that albumin is safe, albeit no more eﬀ ective than isotonic 
saline for ﬂ uid resuscitation [25]. Th e study demonstrated 
no diﬀ erence in need for and duration of RRT [25]. Very 
few patients in the trial received large volume ﬂ uid 
resuscitation (>5 l) and thus the results may not be 
applicable to all patients.
Hydroxyethylstarch (HES) is a widely used, relatively 
inexpensive alternative to human albumin for correcting 
hypovolemia. A recent Cochrane review concluded that 
there is no evidence that resuscitation with colloids, 
instead of crystalloids, reduces the risk of death in 
patients with trauma, burns, or following surgery [26]. In 
addition to some negative eﬀ ects on coagulation, particu-
larly with older forms of HES, development of renal 
dysfunction has been a concern associated with the use 
of mainly hypertonic HES. A recent meta-analysis des-
cribed 11 randomized trials with a total of 1,220 patients: 
seven trials evaluating hyperoncotic albumin and four 
trials evaluating hyperoncotic starch [27]. Hyperoncotic 
albumin decreased the odds of AKI by 76% while 
hyperoncotic starch increased those odds by 92% (odds 
ratio (OR) = 1.92; 95% conﬁ dence interval (CI) = 1.31 to 
2.81; P  =  0.0008). Parallel eﬀ ects on mortality were 
observed. Th e renal eﬀ ects of hyperoncotic colloid 
solutions appeared to be colloid speciﬁ c, with albumin 
displaying renoprotection and hyper oncotic starch 
showing nephrotoxicity. A 7,000-patient study comparing 
6% HES 130/0.4 in saline with saline alone was scheduled 
to begin in Australia and New Zealand in 2010. Th is 
study will provide further high-quality data to help guide 
clinical practice [28].
Th e use of isotonic saline as the standard of care for 
intravascular volume expansion to prevent or treat AKI is 
thus based upon the lack of clear evidence that colloids 
are superior for this purpose, along with some evidence 
that speciﬁ c colloids may cause AKI, in addition to their 
higher costs. It is acknowledged that colloids may be 
chosen in some patients to aid in reaching resuscitation 
goals, or to avoid excessive ﬂ uid administration in 
patients requiring large volume resuscitation, or in 
Figure 2. Stage-based management of acute kidney injury. Shading of boxes indicates priority of action: solid shading, actions that are equally 
appropriate at all stages; graded shading, increasing priority as intensity increases. AKI, acute kidney injury.
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speciﬁ c patient subsets (for example, a cirrhotic patient 
with spontaneous peritonitis, or in burns). Similarly, 
although hypotonic or hypertonic crystalloids may be 
used in speciﬁ c clinical scenarios, the choice of crystal-
loid with altered tonicity is generally dictated by goals 
other than intravascular volume expansion (for example, 
hypernatremia or hyponatremia). In addition, isotonic 
saline solution contains 154  mmol/l chloride and when 
administration in large volumes will result in relative or 
absolute hyperchloremia (for a review, see Kaplan and 
Kellum [29]). Buﬀ ered salt solutions approximate physio-
logical chloride concentrations and cause less acid–base 
disturbances and other side eﬀ ects associated with 
hyperchloremia. Whether the use of buﬀ ered solutions 
results in better clinical outcomes, however, is uncertain. 
Once the intravascular volume has been optimized, it is 
not known which vasopressor agent is most eﬀ ective for 
manage ment of shock in general, or for the kidney speci-
ﬁ  cally. A large RCT comparing dopamine with nor-
epinephrine as the initial vasopressor in patients with 
shock showed no signiﬁ cant diﬀ erences between groups 
with regard to renal function or mortality. However, 
there were more arrhythmic events among the patients 
treated with dopamine [30]. Vasopressin is gaining 
popularity in the treatment of shock refractory to 
norepinephrine [31]. Compared with norepinephrine, 
vasopressin increases blood pressure and enhances 
diuresis, but has not been proven to enhance survival or 
to reduce the need for RRT [32]. Although there is some 
suggestion that vasopressin may reduce progression to 
renal failure and mortality in patients with septic shock 
[33], the Work Group concluded that current clinical 
data are insuﬃ   cient to recommend one vasoactive agent 
over another in preventing AKI, but emphasized that 
vasoactive agents should not be withheld from patients 
with vasomotor shock over concern for kidney perfusion. 
Indeed, appro priate use of vasoactive agents can improve 
kidney perfusion in volume-resuscitated patients with 
vaso motor shock.
While the risks and beneﬁ ts of so-called early goal-
directed therapy are unclear and three large trials are 
underway in the USA, Australia and the UK, there is 
some evidence that protocolized resuscitation may be 
better than standard care. A recent meta-analysis con-
cluded that protocolized therapies (regardless of the 
protocol) with speciﬁ c physiological goals can signiﬁ -
cantly reduce postoperative AKI [34]. A problem in 
interpreting these studies is the lack of standardized 
hemodynamic and tissue oxygenation targets and 
manage ment strategies used to verify the eﬃ  cacy of these 
measures over standard perioperative care. A hetero-
geneous collection of study populations, types of surgical 
procedures, monitoring methods, and treatment strate-
gies comprise this recent meta-analysis [34]. Th e basic 
strategy of goal-directed therapy to prevent AKI in the 
perioperative period is based on protocols that avoid 
hypotension, optimize oxygen delivery, and include care-
ful ﬂ uid management, vasopressors when indicated, and 
inotropic agents and blood products if needed [34]. 
Given the limitations of the current studies and the lack 
of comparative eﬀ ectiveness studies of individual proto-
cols, we can only conclude that protocols for resuscitation 
in the setting of septic shock and high-risk surgery 
appear to be superior to no protocol.
D1:  In the absence of hemorrhagic shock, we 
suggest using isotonic crystalloids rather than 
colloids (albumin or starches) as initial 
management for expansion of intravascular 
volume in patients at risk for AKI or with AKI 
(Grade 2B).
D2: We recommend the use of vasopressors in 
conjunction with ﬂ uids in patients with 
vasomotor shock with, or at risk for, AKI (Grade 
1C).
D3:  We suggest using protocol-based management 
of hemodynamic and oxygenation parameters to 
prevent development or worsening of AKI in 
high-risk patients in the perioperative setting 
(Grade 2C) or in patients with septic shock 
(Grade 2C).
Nutrition and glycemic control
Pooled analyses of early multicenter studies have failed to 
conﬁ rm the early observations of beneﬁ cial eﬀ ects of 
intensive insulin therapy on renal function; the risk of 
hypoglycemia with this approach is signiﬁ cant, and the 
survival beneﬁ ts of intensive insulin therapy are in doubt 
[35,36]. Th e international Normoglycemia in Intensive 
Care Evaluation and Survival Using Glucose Algorithm 
Regulation study found a 90-day mortality of 27.5% in the 
intensive insulin therapy group (target blood glucose 
range 81 to 108 mg/dl (4.5 to 6.0 mmol/l)) and a 90-day 
mortality of 24.9% in the conventional glucose control 
(target ≤180  mg/dl (≤10.0  mmol/l)) (OR for intensive 
control = 1.14; 95% CI = 1.02 to 1.28; P = 0.02) [37]. Th e 
treatment eﬀ ect did not diﬀ er signiﬁ cantly between 
surgical patients and medical patients. Th ere was no 
signiﬁ cant diﬀ erence between the two treatment groups 
in incidence of new RRT (15.4% vs. 14.5%). Severe hypo-
glycemia (blood glucose level ≤40  mg/dl (≤2.2  mmol/l)) 
was reported in 6.8% in the intensive-control group and 
in 0.5% in the conventional-control group (P  <0.001). 
Considering the balance between potential beneﬁ ts and 
harm, the Work Group suggests using insulin for 
preventing severe hyperglycemia in critically ill patients 
but in view of the danger of potentially serious 
hypoglycemia, we suggest that the average blood glucose 
should not exceed 149  mg/dl (8.3  mmol/l), but that 
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insulin therapy should not be used to lower blood glucose 
to <110 mg/dl (6.1 mmol/l). Th e Work Group recognizes 
that these thresholds have never directly been examined 
in RCTs but are interpolated from the comparisons so far 
tested in the trials.
Several expert panels have developed clinical practice 
guidelines for the nutritional management of patients 
with AKI, whether treated with or without RRT [38-42]. 
Observations in critically ill patients provide a rationale 
to maintain a total energy intake of at least 20  kcal/kg/
day but not more than 25 to 30 kcal/kg/day, equivalent to 
100 to 130% of the resting energy expenditure. Energy 
provision should be composed of 3 to 5 g (maximum 7 g) 
per kilogram body weight carbohydrates and 0.8 to 1.0 g 
per kilogram body weight fat.
When continuous renal replacement therapy (CRRT) 
techniques are used it should be realized that they may 
result in additional losses of water-soluble, low-
molecular-weight substances, including nutrients [43]. 
Normalized protein catabolic rates of 1.4 to 1.8 g/kg/day 
have been reported in patients with AKI receiving CRRT 
[44-46] and about 0.2 g amino acids are lost per liter of 
ﬁ ltrate, amounting to a total daily loss of 10 to 15 g amino 
acids. In addition, 5 to 10  g protein are lost per day, 
depending on the type of therapy and dialyzer membrane. 
Similar amounts of protein and amino acids are typically 
lost by peritoneal dialysis. Nutritional support should 
account for these losses by providing a maximum of 1.7 g 
amino acids/kg/day. Enteral feeding is associated with 
improved outcome/survival in ICU patients [47,48] and 
should be recommended for patients with AKI.
In children with AKI, physiological macronutrient 
requirements are age dependent, reﬂ ecting the develop-
mental dynamics of growth and metabolism. Although 
these recommendations are limited to observational 
studies, it is generally agreed that critically ill children, 
like adults, should receive 100 to 130% of the basal energy 
expenditure, which can be estimated with acceptable 
precision and accuracy by the Caldwell–Kennedy 
equation [49]:
Resting energy expenditure (kcal/kg/day) = 
22 + 31.05 × weight (kg) + 1.16 × age (years)
In a recent survey of the nutritional management of 
195 children with AKI on CRRT, the maximal calorie 
prescription in the course of treatment averaged 53, 31, 
and 21  kcal/kg/day, and that for protein intake 2.4, 1.9, 
and 1.3 g/kg/day in children aged <1 year, 1 to 13 years, 
and >13 years, respectively [50]. Although not validated 
by outcome studies, these ﬁ gures provide an orientation 
for the macronutrient supply typically achieved in and 
tolerated by children with AKI receiving CRRT.
D4: In critically ill patients, we suggest insulin 
therapy targeting plasma glucose 110 to 
149 mg/dl (6.1 to 8.3 mmol/l) (Grade 2C).
D5: We suggest achieving a total energy intake of 20 
to 30 kcal/kg/day in patients with any stage of 
AKI (Grade 2C).
D6: We suggest avoiding restriction of protein 
intake with the aim of preventing or delaying 
initiation of RRT (Grade 2D).
D7: We suggest administering 0.8 to 1.0 g/kg/day 
protein in noncatabolic AKI patients without 
need for dialysis (Grade 2D), 1.0 to 1.5 g/kg/day 
in patients with AKI on RRT (Grade 2D), and up 
to a maximum of 1.7 g/kg/day in patients on 
CRRT and in hypercatabolic patients (Grade 
2D).
D8: We suggest providing nutrition preferentially 
via the enteral route in patients with AKI 
(Grade 2C).
Diuretics
On the basis of various mechanistic studies and support 
from preclinical data [51-54], loop diuretics (especially 
furosemide) have long been prescribed in the acute-care 
setting [55-57], and a number of RCTs have tested 
whether furosemide is beneﬁ cial for prevention or treat-
ment of AKI. Speciﬁ cally, prophylactic furosemide was 
found to be ineﬀ ective or harmful when used to prevent 
AKI after cardiac surgery [52,53], and to increase the risk 
of AKI when given to prevent contrast-induced AKI [54]. 
Epidemiologic data suggest that the use of loop diuretics 
may increase mortality in patients with critical illness 
and AKI [58], along with conﬂ icting data that suggest no 
harm in AKI [59]. Finally, furosemide therapy was also 
ineﬀ ective and possibly harmful when used to treat AKI 
[51,60]. A systematic review and meta-analysis by Ho and 
Power also included six studies that used furosemide to 
treat AKI, with doses ranging from 600 to 3,400 mg/day 
[61]. No signiﬁ cant reduction was found for in-hospital 
mortality or for RRT requirement. Furosemide may be 
useful in achieving ﬂ uid balance to facilitate mechanical 
ventilation according to the lung-protective ventilation 
strategy in hemodynamically stable patients with acute 
lung injury. However, a beneﬁ cial role for loop diuretics 
in facilitating discontinuation of RRT in AKI is not 
evident from clinical studies [62,63].
Th e often retrospective and/or underpowered studies 
using prophylactic mannitol did not meet the criteria of 
the Work Group to be included in formulation of recom-
mendations. Mannitol is often added to the priming ﬂ uid 
of the cardiopulmonary bypass system to reduce the 
incidence of renal dysfunction, but the results of these 
studies are not very convincing [64]. Two small random-
ized trials  – one in patients with pre-existing normal 
renal function [65], the second in patients with estab-
lished renal dysfunction [66]  – did not ﬁ nd diﬀ erences 
for any measured variable of renal function. More 
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convincing are the results obtained with the preventive 
administration of mannitol, just before clamp release, 
during renal transplantation [67,68]. Th e sparse con-
trolled data available have shown that 250  ml of 20% 
mannitol given immediately before vessel clamp removal 
reduces the incidence of post-transplant AKI, as indi-
cated by a lower requirement of post-transplant dialysis. 
However, 3 months after transplantation, no diﬀ erence is 
found in kidney function compared with patients who 
did not receive mannitol [69]. Finally, it has been 
suggested that mannitol is beneﬁ cial in rhabdomyolysis 
by stimulating osmotic diuresis and by lowering the 
intracompartmental pressure in the aﬀ ected crushed 
limbs [70-72]; again, these studies were either not 
random ized or were underpowered. A separate guideline 
on crush injury associated with disasters, mainly earth-
quake victims, has now been published by the Inter-
national Society of Nephrology Renal Disaster Relief Task 
Force [73].
D9:  We recommend not using diuretics to prevent 
AKI (Grade 1B).
D10:  We suggest not using diuretics to treat AKI, 
except in the management of volume overload 
(Grade 2C).
Vasodilator therapy: dopamine, fenoldopam, and natriuretic 
peptides
Th ree systematic reviews have reached identical conclu-
sions that dopamine does not provide any beneﬁ t for 
prevention or early treatment of AKI [74-76]. Th ere is 
also limited evidence that the use of dopamine to prevent 
or treat AKI causes harm. Dopamine can trigger tachy-
arrhythmias and myocardial ischemia, decrease intestinal 
blood ﬂ ow, cause hypopituitarism, and suppress T-cell 
function [77]. Fenoldopam mesylate is a pure dopamine 
type-1 receptor agonist that has similar hemodynamic 
renal eﬀ ects as low-dose dopamine, without systemic α-
adrenergic or β-adrenergic stimulation [78]. A meta-
analysis found that fenoldopam reduces the need for RRT 
and in-hospital death in cardiovascular surgery patients 
[79]. However, the pooled studies included both pro phy-
lactic and early therapeutic studies, as well as propensity-
adjusted case-matched studies (rather than purely 
random ized trials). A 1,000-patient RCT of fenoldopam 
to prevent the need for RRT after cardiac surgery is 
currently underway (ClinicalTrials.gov: NCT00621790); 
meanwhile, this remains an unproven indication for 
fenoldopam therapy.
Our analysis of existing data from suitable prophylactic 
studies of adequate size and study design that reported 
AKI incidence in patients randomized to fenoldopam 
versus placebo revealed a pooled relative risk (RR) of 0.96 
(95% CI = 0.76 to 1.2; P = not signiﬁ cant). Only one study 
reported mortality (8-day) in sepsis patients randomized 
to fenoldo pam (35%, n  =  150) versus placebo (44%, 
n = 150), with a RR of 0.79 (95% CI = 0.59 to 1.05; P = 0.1) 
[80]. As therapy for AKI, only one study reported 
(21-day) mortality in critically ill patients with early AKI 
random ized to fenoldopam (11/80, 13.8%) versus placebo 
(n = 19/75, 25.3%; P = 0.068) [81]. Another study reported 
the change in renal function in AKI patients randomized 
to fenoldopam (n = 50) versus dopamine (n = 50), deﬁ ned 
by the absolute SCr change between the beginning and 
end of the study drug infusion and the maximum 
decrease from study entry, which were signiﬁ cantly larger 
in the fenoldopam group: -0.53  ±  0.47 vs. dopamine: 
-0.34 ± 0.38 md/dl, P = 0.027 [82]. Overall, therefore, no 
data from adequately powered multicenter trials with 
clini cally signiﬁ cant end-points and adequate safety are 
available to recommend fenoldopam to either prevent or 
treat AKI. Th e guideline recommendation against using 
fenoldopam places a high value on avoiding potential 
hypotension and harm associated with the use of this 
vasodilator in high-risk perioperative and ICU patients, 
and a low value on potential beneﬁ t, which is currently 
only suggested by relatively low-quality single-center 
trials.
Nigwekar and colleagues recently conducted a syste-
matic review and meta-analysis of ANP for manage ment 
of AKI [83]. Th ey found 19 relevant studies, among which 
11 studies were for prevention and eight were for treat-
ment of AKI. Pooled analysis of the eight treatment 
studies, involving 1,043 participants, did not show 
signiﬁ cant diﬀ erence for either RRT requirement or 
mortality between the ANP and control groups. However, 
low-dose ANP preparations were associated with signiﬁ -
cant reduction in RRT requirement (OR = 0.34; 95% CI = 
0.12 to 0.96; P = 0.04). Th e incidence of hypotension was 
not diﬀ erent between the ANP and control groups for 
low-dose studies, whereas it was signiﬁ cantly higher in 
the ANP group in the high-dose ANP studies (OR = 4.13; 
95% CI  = 1.38 to 12.41; P  <  0.01). Finally, a pooled 
analysis of studies that examined oliguric AKI did not 
show any signiﬁ cant beneﬁ t from ANP for RRT require-
ment or mortality. Only two of the treatment studies 
included in Nigwekar and colleagues’ analysis [84,85] 
were of adequate size and quality to meet the criteria for 
our systematic review, which found no signiﬁ cant incon-
sistencies in the ﬁ ndings of both trials that (combined) 
included 720 subjects (351 treated with ANP). Th erefore, 
although subset analyses separating low-dose from high-
dose ANP trials suggest potential beneﬁ ts, the pre pon-
derance of the literature suggests no beneﬁ t of ANP 
therapy for AKI. Th e Work Group therefore suggests this 
agent not to be used to prevent or treat AKI.
Nesiritide (b-type natriuretic peptide) is the latest 
natriuretic peptide introduced for clinical use, and is 
approved by the US Food and Drug Administration only 
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for the therapy of acute, decompensated congestive heart 
failure. Meta-analysis of outcome data from these and 
some other nesiritide congestive heart failure trials has 
generated some controversy [86-88]. Sackner-Bernstein 
and colleagues analyzed mortality data from 12 random-
ized trials; three trials provided 30-day mortality data, 
and found a trend towards an increased risk of death in 
nesiritide-treated subjects [86]. In another meta-analysis 
of ﬁ ve randomized trials that included 1,269 subjects 
[87], the same investigators found that there was a 
relationship between nesiritide use and worsening renal 
function, deﬁ ned as SCr increase >0.5 mg/dl (>44.2 μmol/
l). Nesiritide doses ≤0.03 μg/kg/minute and even at doses 
≤0.015  μg/kg/minute signiﬁ cantly increased the risk of 
renal dysfunction compared with non-inotrope-based 
controls or compared with all control groups (including 
inotropes). Th ere was no diﬀ erence in dialysis rates 
between the groups. Another retrospective study deter-
mined independent risk factors for 60-day mortality by 
multivariate analysis in a cohort of 682 older heart-failure 
patients treated with nesiritide versus those who were 
not [89]. When patients were stratiﬁ ed according to 
nesiritide usage, AKI emerged as an independent risk 
factor for mortality only among patients who received 
the drug. Strikingly, among these heart-failure patients 
who developed AKI, nesiritide usage emerged as the only 
independent predictor of mortality. A 7,000-patient 
multicenter RCT in acute decompensated heart failure 
has recently assessed the clinical eﬀ ective ness of nesiritide 
therapy for acute decompensated heart failure (the Acute 
Study of Clinical Eﬀ ectiveness of Nesiritide in Decom pen-
sated Heart Failure; Clinicaltrials.gov: NCT00475852).
A prospective, randomized clinical trial (the Nesiritide 
Study) found no beneﬁ t of nesiritide for 21-day dialysis 
and/or death in patients undergoing high-risk cardio-
vascular surgery [90]. However, this study did demon-
strate that the prophylactic use of nesiritide was asso-
ciated with reduced incidence of AKI in the immediate 
postoperative period (nesiritide 6.6% vs. placebo 28.5%; 
P = 0.004). Recently, Lingegowda and colleagues investi-
gated whether the observed renal beneﬁ ts of nesiritide 
had any long-term impact on cumulative patient survival 
and renal outcomes [91]. Data on all 94 patients from the 
Nesiritide Study were obtained with a mean follow-up 
period of 20.8  ±  10.4  months. No diﬀ erences in 
cumulative survival between the groups were noted, but 
patients with in-hospital incidence of AKI had a higher 
rate of mortality than those with no AKI (41.4% vs. 10.7%; 
P  =  0.002). Th e possible renoprotection provided by 
nesiritide in the immediate postoperative period was not 
associated with improved long-term survival in patients 
undergoing high-risk cardiovascular surgery.
Although evidence from a variety of small studies 
suggests the potential for therapy with natriuretic 
peptides to be useful for the prevention or treatment of 
AKI in a variety of settings, there are no deﬁ nitive trials 
to support the use of atrial natriuretic peptide (ANP), b-
type natriuretic peptide, or nesiritide for these purposes. 
Th e Work Group therefore suggests these agents should 
not be used for prevention or treatment of AKI.
D11:  We recommend not using low-dose dopamine 
to prevent or treat AKI (Grade 1A).
D12:  We suggest not using fenoldopam to prevent or 
treat AKI (Grade 2C).
D13: We suggest not using ANP to prevent (Grade 
2C) or treat (Grade 2B) AKI.
Other pharmacologic therapies
AKI occurs in 60% of neonates suﬀ ering from perinatal 
asphyxia [92], and experimental studies have indicated an 
important role for adenosine-mediated vasoconstriction 
in neonatal kidneys exposed to normocapnic hypoxemia 
[93]. A potential renoprotective eﬀ ect of theophylline in 
perinatal asphyxia has been assessed in three random-
ized, placebo-controlled clinical trials [94-96], including 
a total of 171 term neonates. Th eophylline was uniformly 
administered in the ﬁ rst hour of life as a single intra-
venous bolus at a dose of 5 mg/kg [94,96] or 8 mg/kg [95]. 
All three studies observed signiﬁ cantly higher glomerular 
ﬁ ltration rate, higher urine output with more negative 
ﬂ uid balance, and lower urinary β2-microglobulin excre-
tion with theophylline as compared with placebo during 
the ﬁ rst 3 to 5  days of life. In each study, theophylline 
treatment was associated with a signiﬁ cantly reduced risk 
of severe renal dysfunction (17 to 25% vs. 55 to 60% in 
the placebo group; RR = 0.3 to 0.41). Th e beneﬁ cial eﬀ ect 
was selective for kidney function, whereas the incidence 
of extra-renal complications was unaltered. Patient 
survival was not aﬀ ected by treatment. In line with these 
studies in mature neonates, a similar improvement of 
glomerular ﬁ ltration rate and urine output was observed 
during the ﬁ rst 2 days of life by administration of 1 mg/kg 
theophylline versus placebo in 50 very preterm neonates 
with respiratory distress syndrome [97]. Follow-up of 
renal function throughout the ﬁ rst year of life by Bhat 
and colleagues found equally normal glomerular and 
tubular function in both groups from 6  weeks of age 
onward [95]. Hence, while theophylline clearly improves 
renal function in the ﬁ rst week of life in postasphyctic 
neonates, the overall beneﬁ t from this intervention in 
neonatal intensive care is less evident in view of the 
complete long-term recovery of renal function in the 
placebo-treated controls and the absence of an eﬀ ect on 
patient survival.
By contrast, adenosine antagonism does not appear 
beneﬁ cial in cardiorenal syndrome. Th ree pivotal phase 
III trials in a total of 2,500 patients were recently 
completed, aiming to corroborate the renoprotective 
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eﬀ ects of rolofylline in patients with cardiorenal syn-
drome, and to establish drug safety. Th e ﬁ nal results of 
the PROTECT trial have recently been published [98]. 
Rolofylline, as compared with placebo, did not provide a 
beneﬁ t with respect to the three primary end-points: 
survival, heart-failure status, and changes in renal 
function. Persistent renal impairment developed in 15.0% 
of patients in the rolofylline group and in 13.7% of 
patients in the placebo group (P = 0.44). By 60 days, death 
or readmission for cardiovascular or renal causes had 
occurred in similar proportions of both groups of 
patients. Adverse-event rates were similar overall; how-
ever, only patients in the rolofylline group had seizures, a 
known potential adverse eﬀ ect of A1-receptor antago-
nists. Rolofylline therefore does not appear to be eﬀ ective 
for treatment of cardiorenal AKI.
Based on an analysis of the three RCTs with insulin-like 
growth factor-1 that are currently available [99-101] and 
which were overall negative or at least equivocal, the 
Work Group recommends against its use in patients with 
AKI.
D14:  We recommend not using recombinant human 
insulin-like growth factor-1 to prevent or treat 
AKI (Grade 1B).
D15:  We suggest that a single dose of theophylline 
may be given in neonates with severe perinatal 
asphyxia, who are at high risk of AKI (Grade 
2B).
Avoiding nephrotoxins
Aminoglycosides exhibit a number of favorable pharma-
co kinetic and pharmacodynamic advantages, but a major 
dose-limiting toxicity of the aminoglycosides remains the 
risk of drug-induced AKI [102]. Th e risk of AKI attri bu-
table to aminoglycosides is suﬃ  ciently high (up to 25% in 
some series, depending upon the deﬁ nition of AKI used 
and the population studied) [103-109] that they should 
no longer be used for standard empirical or directed 
treatment, unless no other suitable alternatives exist.
When still required, the potential eﬃ  cacy of single-
dose daily regimens (or other extended dosing treatment 
programs) of aminoglycosides versus multiple-daily dosing 
strategies has been extensively studied in numerous 
controlled and uncontrolled clinical studies over many 
years [110-121], and the subject has been the focus of a 
number of formal meta-analyses [122-127]. Th e cumu-
lative results of this evidence-based review and numerous 
meta-analyses indicate that once-daily dosing strategies 
generally result in less AKI when compared with 
multiple-dose dosing strategies, although the beneﬁ t 
accrued by the single-daily dose strategy is modest and 
inconsistent across a number of these studies.
In view of the high variability of the pharmacokinetic 
characteristics of aminoglycosides, therapeutic drug 
monitor ing in combination with or independent from 
single-dose daily treatment regimens is recommended. In 
single-dose or extended-dose treatment strategies, the 
peak drug level should be at least 10-fold greater than the 
minimum inhibitory concentration of the infecting 
microorganism. Th e trough level should be undetectable 
by 18 to 24 hours to limit accumulation of amino glyco-
sides in renal tubular cells and to minimize the risk of 
AKI.
Aminoglycoside aerosol delivery systems are now in 
use to provide high intrapulmonary antibiotic levels with 
minimal systemic and kidney concentrations of the 
antibiotic. However, signiﬁ cant nephrotoxicity with the 
use of inhaled tobramycin has been described in at least 
two cases [128,129].
Th e safety and eﬃ  cacy of lipid formulations of ampho-
tericin B have been studied in numerous experimental 
and clinical trials with conventional amphotericin B as 
the comparator [130-142]. A detailed analysis of these 
various trials, and a number of meta-analyses that have 
analyzed this clinical question, concluded that the lipid 
formulations are less nephrotoxic than amphotericin B 
deoxycholate [133,135]. When feasible, we recommend 
that lipid formulations supplant the use of conventional 
amphotericin B to reduce the risk of nephrotoxicity. 
Alternatively, when feasible, it may be best to avoid 
polyene antifungal agents entirely and use alternative 
agents, such as the azoles and echinocandins [143-147].
D16:  We suggest not using aminoglycosides for the 
treatment of infections unless no suitable, less 
nephrotoxic, therapeutic alternatives are 
available (Grade 2A).
D17:  We suggest that, in patients with normal kidney 
function in steady state, aminoglycosides are 
administered as a single dose daily rather than 
multiple-dose daily treatment regimens 
(Grade 2B).
D18: We recommend monitoring aminoglycoside 
drug levels when treatment with multiple daily 
dosing is used for more than 24 hours (Grade 
1A).
D19:  We suggest monitoring aminoglycoside drug 
levels when treatment with single-daily dosing 
is used for more than 48 hours (Grade 2C).
D20:  We suggest using topical or local applications of 
aminoglycosides (for example, respiratory 
aerosols, instilled antibiotic beads), rather than 
intravenous application, when feasible and 
suitable (Grade 2B).
D21:  We suggest using lipid formulations of 
amphotericin B rather than conventional 
formulations of amphotericin B (Grade 2A).
D22:  In the treatment of systemic mycoses or 
parasitic infections, we recommend using azole 
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antifungal agents and/or the echinocandins 
rather than conventional amphotericin B, if 
equal therapeutic eﬃ  cacy can be assumed 
(Grade 1A).
Surgical patients
A comprehensive meta-analysis examining oﬀ -pump 
versus conventional coronary artery bypass surgery 
found that the oﬀ -pump technique was associated with a 
statistically signiﬁ cant 40% lower odds of postoperative 
AKI and a nonsigniﬁ cant 33% lower odds for dialysis 
requirement [148]. Within the selected trials, oﬀ -pump 
coronary artery bypass graft surgery was not associated 
with a signiﬁ cant decrease in mortality. It is apparent 
from this meta-analysis that the trials were clinically 
heterogeneous, particularly with regard to their deﬁ ni-
tions of kidney outcomes, and mostly were of poor to fair 
quality (based on the Jadad score). Th e very low event 
rates (often zero or one patient) make the estimates 
suspect and highly imprecise. Th ere is also a question of 
publication bias. Th ere are several large trials in progress 
that are likely to generate more deﬁ nitive data. Th e Work 
Group concluded that there was not enough evidence at 
present to recommend oﬀ -pump coronary artery bypass 
for reducing AKI or the need for RRT.
A meta-analysis did not ﬁ nd evidence that N-acetyl-
cysteine used perioperatively could alter mortality or 
renal outcomes after major cardiovascular or abdominal 
cancer surgery when radiocontrast agents are not used 
[149]. Only a single study has compared N-acetyl cysteine 
with placebo in critically ill patients with hypotension 
and was also negative [150].
D23: We suggest that oﬀ -pump coronary artery 
bypass graft surgery not be selected solely for 
the purpose of reducing perioperative AKI or 
need for RRT (Grade 2C).
D24: We suggest not using N-acetylcysteine to 
prevent AKI in critically ill patients with 
hypotension (Grade 2D).
D25:  We recommend not using oral or intravenous 
N-acetylcysteine for prevention of postsurgical 
AKI (Grade 1A).
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